Axsome Therapeutics (AXSM) Projected to Post Quarterly Earnings on Monday

Key Points

• Axsome Therapeutics is expected to report Q3 2026 results on November 2, with analysts forecasting a loss of $0.62 per share and revenue of approximately $250.2 million. The company previously missed estimates, reporting a $0.99 per-share loss and $218.4 million in revenue.
• AXSM shares opened at $145.04, well below their 50-day and 200-day moving averages of $191.71 and $212.44, respectively. The stock has traded between $123.50 and $260.19 over the past year.
• Wall Street’s overall view remains positive, with a “Moderate Buy” consensus and an average price target of $275.74, although insiders have sold nearly 60,000 shares worth $12.6 million in the past quarter.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) is expected to post its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.6215) per share and revenue of $250.22 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:00 AM ET.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. The business had revenue of $218.38 million for the quarter, compared to analysts' expectations of $221.11 million. On average, analysts expect Axsome Therapeutics to post ($2.97) EPS for the current fiscal year and $3.64 EPS for the next fiscal year.

Axsome Therapeutics Stock Performance

Shares of NASDAQ:AXSM opened at $145.04 on Monday. The business's 50-day moving average is $191.71 and its 200 day moving average is $212.44. Axsome Therapeutics has a 1 year low of $123.50 and a 1 year high of $260.19. The firm has a market capitalization of $7.60 billion, a P/E ratio of -38.68 and a beta of 0.86. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34.

Insider Activity

In other news, COO Mark L. Jacobson sold 10,000 shares of the firm's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the completion of the transaction, the chief operating officer directly owned 10,000 shares in the company, valued at $2,086,500. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Herriot Tabuteau sold 4,660 shares of Axsome Therapeutics stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $213.95, for a total value of $997,007.00. Following the sale, the chief executive officer directly owned 7,229 shares of the company's stock, valued at $1,546,644.55. This trade represents a 39.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 59,664 shares of company stock worth $12,624,805. Company insiders own 20.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AXSM. Weiss Ratings restated a "sell (d-)" rating on shares of Axsome Therapeutics in a research note on Thursday, October 15th. BMO Capital Markets initiated coverage on shares of Axsome Therapeutics in a research note on Monday, July 20th. They issued an "outperform" rating and a $310.00 target price for the company. Mizuho lifted their target price on shares of Axsome Therapeutics from $306.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. Piper Sandler reissued an "overweight" rating and set a $258.00 target price on shares of Axsome Therapeutics in a research report on Friday, September 18th. Finally, Morgan Stanley cut their price target on shares of Axsome Therapeutics from $251.00 to $247.00 and set an "equal weight" rating on the stock in a research note on Friday, September 25th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $275.74.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome's commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.